Core Insights - Ernexa Therapeutics is advancing its lead product candidate ERNA-101 towards a first-in-human clinical trial for platinum-resistant ovarian cancer, with an IND submission expected in Q3 2026 and trial initiation planned for Q4 2026 [1][2][14] - The company has reported significant preclinical data showing durable tumor regressions and prolonged survival in ovarian cancer models when ERNA-101 is combined with PD-1 blockade, indicating its potential as a foundational immunotherapy platform [3][8] - Ernexa is also developing ERNA-201, an engineered anti-inflammatory therapy targeting autoimmune diseases, alongside the advancement of ERNA-101 [5][12] Company Progress - Ernexa has streamlined operations, reducing general and administrative expenses by approximately 61% year over year while maintaining focus on core programs [9] - The company completed Proof of Principle studies for both ERNA-101 and ERNA-201 and successfully held a Pre-IND meeting with the FDA for ERNA-101 [9][10] Upcoming Milestones - Key milestones include the completion of ERNA-101 clinical manufacturing process development in Q2 2026, IND-enabling preclinical studies in Q3 2026, and the initiation of the first-in-human Phase 1 clinical study in Q4 2026 [14] - Initial clinical data readout from ERNA-101 is expected in the first half of 2027, with advancement into Phase 2 trials anticipated in the second half of 2027 [14]

Financial Condition - As of December 31, 2025, the company had an accumulated deficit of approximately $245.6 million[99]. - The company has incurred significant net losses since inception and expects to continue incurring losses for the foreseeable future[100]. - As of December 31, 2025, the company's stockholders' equity was approximately $2.4 million, and it completed a public offering in February 2026, raising net proceeds of about $9.5 million[127]. - The company may need to raise substantial additional capital to fund operations and execute its business strategy, with no assurance of obtaining it on favorable terms[93]. - The company may experience substantial dilution of existing stockholder ownership if additional capital is raised through equity or equity-linked securities[96]. - The company has not been profitable since commencing operations and may never achieve profitability, which could adversely impact its stock price and ability to raise capital[100]. Regulatory Risks - The regulatory approval process for the company's cellular therapy product candidates is uncertain and may be more expensive and time-consuming than for other therapeutic approaches[116]. - The FDA's evolving regulatory requirements for cellular therapy products may cause delays and increase costs for the company's product candidates[118]. - The regulatory approval processes by the FDA and comparable foreign authorities are lengthy and unpredictable, typically taking many years after clinical studies commence[141]. - If future product candidates do not receive regulatory approval, the company's business, prospects, and financial condition will be adversely affected[142]. - Delays in clinical studies can occur due to changes in regulatory requirements or unexpected events, potentially increasing costs and delaying development timelines[143]. - The FDA may impose clinical holds or require additional studies, which could further delay the approval process[144]. - Disruptions at the FDA due to funding shortages or other external factors could negatively impact the company's ability to obtain timely reviews and approvals[145]. - Regulatory agencies may impose limitations on approved product indications, which could affect commercialization efforts[140]. - The company may need to change regulatory strategies or modify applications, potentially delaying product development and approval[119]. Market Competition - The company faces intense competition from larger pharmaceutical and biotechnology firms, which may have more resources and could develop superior therapies[121]. - The company may face challenges in attracting and retaining highly qualified personnel, impacting its ability to implement its business strategy[113]. Intellectual Property Risks - The company relies heavily on in-licensed intellectual property from Factor Limited, with obligations including $0.2 million per month for the first twelve months and $0.1 million per month for the first nine months toward patent costs[101]. - The company has limited control over the maintenance and enforcement of rights it in-licenses, which could adversely affect its business[103]. - The company relies on maintaining intellectual property rights, and any failure in patent protection could allow competitors to develop similar products, adversely affecting profitability[158]. - The patent application process is expensive and time-consuming, and any defects in patent filings could result in invalid or unenforceable patents, impacting competitive advantage[160]. - The patent position of biotechnology and pharmaceutical companies is highly uncertain, with no consistent policy regarding the breadth of claims allowed in patents, leading to unpredictable outcomes in patent rights[163]. - The lifespan of a patent in the U.S. is generally 20 years from the earliest non-provisional filing date, and even if patents are obtained, they may expire before products are approved and commercialized[165]. - Patent term extensions under the Hatch-Waxman Amendments can provide up to five years of additional protection, but only one patent can be extended per approved product[166]. - Changes in patent law, such as the Leahy-Smith America Invents Act, have increased uncertainties and costs surrounding patent prosecution and enforcement[167]. - Recent court rulings have narrowed the scope of patent protection, creating further uncertainty regarding the validity and enforceability of patents[168]. - Protecting intellectual property rights globally is prohibitively expensive, and rights in some countries may be less extensive than in the U.S.[169]. - Foreign jurisdictions may not favor the enforcement of patents, making it difficult to stop infringement or marketing of competing products[170]. - Litigation to enforce patent rights can be costly and time-consuming, with no guarantee of success, potentially diverting resources from other business aspects[177]. - Adverse outcomes in litigation could result in patents being invalidated or interpreted narrowly, impacting the company's competitive position[178]. - The company may face claims regarding misappropriation of intellectual property from former employees or third parties, which could lead to costly litigation and loss of valuable rights[174]. - The company may face significant expenses and distractions due to ongoing litigation related to intellectual property claims, which could adversely affect its financial performance[179]. - Competitors with greater financial resources may sustain litigation costs more effectively, potentially impacting the company's competitive position in the marketplace[180]. Trademark Risks - The company relies on both registration and common law protection for its trademarks, which may be challenged or infringed, affecting brand recognition and market competitiveness[182]. - Proposed proprietary names for drug candidates must be approved by the FDA, and objections could require significant resources to identify suitable alternatives[183]. - The company may not be able to adequately protect its trademarks, which could lead to diminished goodwill and brand identity in the market[182]. - Trademark registration does not guarantee protection against infringement claims, and competitors may adopt similar names, causing market confusion[183]. - The company may incur additional costs if it needs to respond to trademark rejections or opposition proceedings[182]. - Legal proceedings could substantially increase operating losses and reduce resources available for development and marketing activities[179]. - The company may be liable for monetary damages if found to have willfully infringed a patent, which could further strain financial resources[179]. - The uncertainties from patent litigation could materially affect the company's ability to compete effectively in the marketplace[180]. Market Conditions - The company faces risks related to unstable market conditions, which may hinder its ability to raise additional capital[97]. - Legislative reforms, such as the Inflation Reduction Act, may impose price controls that could adversely affect revenue generation and profitability[151]. - The company faces risks from state-level regulations aimed at controlling pharmaceutical pricing, which may impact product commercialization[152]. - Future healthcare reforms may lead to reduced Medicare funding and lower reimbursement rates, affecting the pricing and demand for approved therapeutic products[153]. - The complexity of manufacturing biotechnology products may lead to production difficulties, impacting development timelines and costs[123].

Company Overview - Ernexa Therapeutics (NASDAQ: ERNA) is focused on developing innovative cell therapies for advanced cancer and autoimmune diseases [4] - The company's core technology involves engineering induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), providing a scalable, off-the-shelf treatment solution [4] Product Pipeline - The lead product, ERNA-101, is designed to activate and regulate the immune system's response to recognize and attack cancer cells, with an initial focus on ovarian cancer [5] - ERNA-201 is another cell therapy product aimed at targeting inflammation and treating autoimmune diseases [5] Upcoming Event - Sanjeev Luther, President & CEO of Ernexa, will participate in the Virtual Investor Closing Bell Series on February 25, 2026, at 4:00 PM ET, providing a corporate overview and business outlook [2][3] - Investors will have the opportunity to submit questions live during the event, with a replay available two hours after the presentation for 90 days [3]

Core Viewpoint - Ernexa Therapeutics Inc. has announced a public offering of 21 million shares of common stock at a price of $0.50 per share, aiming to raise approximately $10.5 million before expenses [1][4]. Group 1: Offering Details - The offering includes warrants to purchase up to 21 million shares at an exercise price of $0.68, which will expire either five years after issuance or 180 days after the release of clinical trial data for ERNA-101 [2]. - The closing of the offering is expected around February 10, 2026, pending customary closing conditions [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to advance development programs, support working capital, and cover general corporate purposes [3]. Group 3: Financial Projections - The total gross proceeds from the offering are estimated at approximately $10.5 million, with potential additional proceeds of about $14.3 million from the exercise of the warrants if fully exercised [4]. Group 4: Company Overview - Ernexa Therapeutics focuses on developing innovative cell therapies for advanced cancer and autoimmune diseases, utilizing induced pluripotent stem cells (iPSCs) to create allogeneic synthetic mesenchymal stem cells (iMSCs) [7]. - The lead product, ERNA-101, is designed to enhance the immune system's ability to target cancer cells, with an initial focus on ovarian cancer treatment [8].

As filed with the Securities and Exchange Commission on February 5, 2026. Registration No. 333-293150 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ERNEXA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 31-1103425 (Primary Standard Industrial Classification Code Number) (IRS Employer Identification ...

As filed with the Securities and Exchange Commission on February 3, 2026. Registration No. 333-293150 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 TO FORM S-1 (State or other jurisdiction of incorporation or organization) Delaware 2834 31-1103425 (Primary Standard Industrial Classification Code Number) (Address, including zip code and telephone number, including area code, of registrant's principal executive offices) Sanjeev Luther President and Chief Executive Off ...

Core Insights - Ernexa Therapeutics is advancing its lead cell therapy, ERNA-101, towards a first-in-human trial for ovarian cancer following a successful Pre-IND meeting with the FDA [2][3] - The FDA's regulatory alignment provides a clear pathway for Ernexa to submit an Investigational New Drug application and initiate clinical testing in the second half of 2026 [3] - The company is currently engaged in technology transfer for clinical-grade manufacturing, enhancing operational readiness for its synthetic, allogeneic induced mesenchymal stem cell (iMSC) therapies [3] Company Overview - Ernexa Therapeutics focuses on developing innovative cell therapies for advanced cancer and autoimmune diseases, utilizing induced pluripotent stem cells (iPSCs) to create induced mesenchymal stem cells (iMSCs) [5] - The company's lead product, ERNA-101, is designed to activate and regulate the immune system's response to cancer cells, while ERNA-201 targets inflammation for autoimmune disease treatment [6] - Ernexa's allogeneic synthetic iMSCs offer a scalable, off-the-shelf treatment solution without the need for patient-specific cell harvesting [5]

As filed with the Securities and Exchange Commission on February 2, 2026. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ERNEXA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 31-1103425 (Primary Standard Industrial Classification Code Number) (IRS Employer Identification No.) 1035 Cambridge Stree ...

Core Insights - Ernexa Therapeutics has been selected as one of ten companies globally to participate in the Japan Entry Acceleration Program (JEAP), highlighting its innovative cell therapy platform for advanced cancer and autoimmune diseases [1][2]. Group 1: Company Overview - Ernexa Therapeutics focuses on developing novel cell therapies, particularly using induced pluripotent stem cells (iPSCs) to create allogeneic synthetic induced mesenchymal stem cells (iMSCs), which provide scalable treatment solutions [7]. - The company’s lead products include ERNA-101, aimed at enhancing the immune system's ability to target tumors, and ERNA-201, which addresses harmful inflammation in autoimmune diseases [5][8]. Group 2: Program Participation - JEAP is a competitive initiative by the Japan External Trade Organization (JETRO), attracting around 70 companies from 25 countries, emphasizing the high level of competition [2][6]. - Participation in JEAP offers Ernexa access to expert mentoring, market-entry guidance, and opportunities for collaboration with leading Japanese research and development organizations [4][6]. Group 3: Strategic Goals - The program is expected to advance Ernexa's pipeline in Japan, with ERNA-101 entering first-in-human clinical trials for ovarian cancer this year, addressing significant unmet needs in cancer treatment [5]. - The company aims to leverage JEAP to explore strategic partnerships and clinical development opportunities, ultimately striving to deliver hope to patients with serious conditions [3].

Core Insights - Ernexa Therapeutics is on track to initiate its first-in-human trial for ovarian cancer treatment in the second half of 2026 following a successful Pre-IND meeting with the FDA, which provided strong regulatory alignment and a clear pathway for IND submission [1][3] Group 1: Company Developments - The company has accelerated key operational activities post-FDA meeting, with tech transfer already underway to prepare for clinical manufacturing and trial readiness [2] - Ernexa is advancing two synthetic, allogeneic induced mesenchymal stem cell (iMSC) therapies: ERNA-101 for ovarian cancer and ERNA-201 for autoimmune disease, utilizing reprogrammed induced pluripotent stem cells (iPSCs) [3][5] - The initial clinical development will focus on ERNA-101, targeting ovarian cancer, which currently has limited effective therapies and high recurrence rates [4][6] Group 2: Technology and Approach - Ernexa's engineered iMSCs are designed to target tumors or inflamed tissues, delivering therapeutic cytokines directly to the disease site, which aims to overcome limitations of traditional MSC therapies while enabling scalable manufacturing [3][5] - The company's approach provides an off-the-shelf treatment option without the need for patient-specific cell harvesting, enhancing patient accessibility [5][6]